Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphedema | 5 | 2020 | 424 | 1.540 |
Why?
|
| Chalcones | 1 | 2020 | 29 | 0.780 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 2017 | 133 | 0.760 |
Why?
|
| Benzofurans | 1 | 2017 | 147 | 0.590 |
Why?
|
| Ions | 1 | 2016 | 264 | 0.560 |
Why?
|
| Adipogenesis | 1 | 2017 | 345 | 0.520 |
Why?
|
| Plant Extracts | 1 | 2017 | 450 | 0.490 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1788 | 0.380 |
Why?
|
| Mice, Inbred ICR | 3 | 2017 | 371 | 0.330 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 1120 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 6320 | 0.210 |
Why?
|
| Microsomes, Liver | 1 | 2020 | 182 | 0.190 |
Why?
|
| Receptors, CXCR3 | 1 | 2021 | 238 | 0.190 |
Why?
|
| Macrophages, Peritoneal | 1 | 2020 | 268 | 0.180 |
Why?
|
| Prodrugs | 1 | 2020 | 273 | 0.170 |
Why?
|
| Toxicodendron | 1 | 2017 | 3 | 0.160 |
Why?
|
| Hindlimb | 2 | 2017 | 545 | 0.160 |
Why?
|
| 3T3-L1 Cells | 1 | 2017 | 209 | 0.150 |
Why?
|
| Calgranulin B | 1 | 2016 | 85 | 0.140 |
Why?
|
| Ascorbic Acid | 1 | 2018 | 639 | 0.130 |
Why?
|
| Aluminum | 1 | 2015 | 138 | 0.130 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 499 | 0.130 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2015 | 131 | 0.130 |
Why?
|
| Flavonoids | 1 | 2017 | 425 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2021 | 894 | 0.120 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 429 | 0.120 |
Why?
|
| Hyaluronic Acid | 1 | 2017 | 499 | 0.120 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 968 | 0.120 |
Why?
|
| Ganglia, Spinal | 1 | 2015 | 506 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2015 | 330 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 2246 | 0.110 |
Why?
|
| Th1 Cells | 1 | 2017 | 1076 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 604 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1192 | 0.100 |
Why?
|
| Fibrosis | 1 | 2017 | 1916 | 0.100 |
Why?
|
| Mice | 6 | 2021 | 80270 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 702 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2017 | 3951 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 4449 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 4264 | 0.080 |
Why?
|
| Animals | 7 | 2021 | 169173 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 18175 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 2528 | 0.060 |
Why?
|
| Proteomics | 1 | 2016 | 3252 | 0.060 |
Why?
|
| Rats | 1 | 2020 | 24794 | 0.060 |
Why?
|
| Chemokine CXCL11 | 1 | 2021 | 42 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2021 | 124 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2015 | 3618 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 6588 | 0.040 |
Why?
|
| Male | 7 | 2017 | 350143 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 12285 | 0.040 |
Why?
|
| Physical Conditioning, Animal | 1 | 2021 | 362 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3050 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 289 | 0.040 |
Why?
|
| Myofibroblasts | 1 | 2017 | 204 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13619 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 20066 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 1150 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 16726 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 12530 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2018 | 10600 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 2095 | 0.020 |
Why?
|
| Spleen | 1 | 2017 | 2458 | 0.020 |
Why?
|
| Apoptosis | 2 | 2018 | 9960 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 8560 | 0.020 |
Why?
|
| Humans | 6 | 2021 | 715594 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 62039 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2017 | 1043 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8888 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 20515 | 0.020 |
Why?
|
| Collagen | 1 | 2017 | 2664 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2017 | 3248 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2016 | 5369 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 6476 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2985 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2017 | 3169 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 162392 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1759 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5190 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 6631 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 15040 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2021 | 23705 | 0.020 |
Why?
|
| Adult | 2 | 2016 | 212237 | 0.020 |
Why?
|
| Middle Aged | 2 | 2016 | 214639 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 7015 | 0.020 |
Why?
|
| Female | 3 | 2021 | 377052 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 9810 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19529 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 28991 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 58293 | 0.010 |
Why?
|
Concepts
(90)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_